GNC Launches Strategic Initiative for GLP-1 Drug Users in Weight Loss Journey

GNC, the well-known vitamin and dietary supplement chain, has been struggling for quite some time now. However, the company believes that a fresh approach specifically aimed at individuals using GLP-1 drugs to aid in weight loss will help attract customers into its stores and grow business. GNC announced on Monday that it would be introducing a dedicated section across its 2300 US locations comprising vitamins, protein shakes, and supplements tailored for people managing their GLP-1 medication such as Ozempic and Wegovy. Furthermore, the company will also provide employee training about common side effects of these drugs along with products to mitigate them.
GNC’s new strategy comes at a time when there is still uncertainty regarding the full impact that GLP-1 (glucagon-like peptide 1 agonists) have on individuals’ overall health, but some people report experiencing side effects such as muscle loss and gastrointestinal issues. The brand wants to be known for providing support through retail outlets to those managing these complications caused by GLP-1 medications.
The Danish pharmaceutical company Novo Nordisk is currently enjoying substantial profits from the creation, production, and sale of hit products such as Wegovy (Semaglutide) that help in weight loss using a drug for diabetes treatment called Ozempic (semaglutide). Other large pharma companies like Pfizer and Roche are also rushing to release their versions into the market. In just three months, US healthcare providers wrote over 9 million prescriptions for Wegovy and other injectable drugs used in weight loss programs. JPMorgan analysts estimate that by 2030, approximately 30 million people or around 9% of the US population could be taking GLP-1 medications.
WeightWatchers has been one of the first brands to build a strategy centered on individuals using these drugs for weight management. The company introduced new membership plans offering members access to doctors who can prescribe these treatments, as well as buying Sequence (a telehealth business) worth more than $100m to supply virtual prescriptions in circumstances deemed necessary by the doctor.
Gyms are also adapting their strategies for individuals taking GLP-1 drugs for weight loss. Luxury gyms such as Life Time have started purchasing clinics that provide medical supervision, while Equinox introduced a personal training program aimed at preserving muscle mass in members who take these medications.
Food companies are also modifying to the trend of consumers on these GLP-1 drugs buying fewer sugary snacks and drinks. JPMorgan reported last year that current users of such medication purchased approximately 8% less food (including high carb, soft drink & snack items) compared with those who weren’t taking them in previous years. Food giants like Nestle have revealed they plan to invest more on producing products beneficial for people undergoing GLP-1 treatment such as Opifast high protein shakes.